Los Angeles, USA
+5 year(s) experience
Dustin joined Datamonitor Healthcare in the summer of 2015. One of the highlights of his role has been analyzing the development of novel therapies from the early pre-clinical and clinical phases, through final approval and marketing authorization. Having been involved in cancer research as a graduate student, Dustin is fascinated by new compounds or mechanisms of action and their impact on the oncology treatment space, both from a clinical and commercial viewpoint.He has a Bachelor of Science in Applied and Computational Mathematics and a PhD in Biological Sciences, both from the University of California, Irvine.
Dustin Writes For
Datamonitor Healthcare: 医療用医薬品の市場調査レポート
Takeda announced the submission of a New Drug Application for ixazomib, the first orally administered proteasome inhibitor for multiple myeloma. On 14 July 2015, Takeda announced the
11 Nov 2015